Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

Peter E. Schwartz; Joseph T. Chambers; Ernest I. Kohorn; Setsuko K. Chambers; Hervey Weitzman; Irene M. Voynick; Neil Maclusky; Frederick Naftolin

doi:10.1002/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

Peter E. Schwartz, Joseph T. Chambers, Ernest I. Kohorn, Setsuko K. Chambers, Hervey Weitzman, Irene M. Voynick, Neil Maclusky, Frederick Naftolin

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist‐antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum) would significantly improve survival. Fifty‐one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression‐free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.

Original language	English (US)
Pages (from-to)	1074-1078
Number of pages	5
Journal	Cancer
Volume	63
Issue number	6
DOIs	https://doi.org/10.1002/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0
State	Published - Mar 15 1989
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0

Cite this

@article{de714a02d240428db379c17b68c8899a,

title = "Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial",

abstract = "One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist‐antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum) would significantly improve survival. Fifty‐one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression‐free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.",

author = "Schwartz, {Peter E.} and Chambers, {Joseph T.} and Kohorn, {Ernest I.} and Chambers, {Setsuko K.} and Hervey Weitzman and Voynick, {Irene M.} and Neil Maclusky and Frederick Naftolin",

year = "1989",

month = mar,

day = "15",

doi = "10.1002/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0",

language = "English (US)",

volume = "63",

pages = "1074--1078",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

AU - Schwartz, Peter E.

AU - Chambers, Joseph T.

AU - Kohorn, Ernest I.

AU - Chambers, Setsuko K.

AU - Weitzman, Hervey

AU - Voynick, Irene M.

AU - Maclusky, Neil

AU - Naftolin, Frederick

PY - 1989/3/15

Y1 - 1989/3/15

N2 - One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist‐antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum) would significantly improve survival. Fifty‐one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression‐free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.

AB - One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist‐antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum) would significantly improve survival. Fifty‐one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression‐free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.

UR - http://www.scopus.com/inward/record.url?scp=0024505272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024505272&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0

DO - 10.1002/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0

M3 - Article

C2 - 2917311

AN - SCOPUS:0024505272

SN - 0008-543X

VL - 63

SP - 1074

EP - 1078

JO - Cancer

JF - Cancer

IS - 6

ER -

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this